Richard Harris

Richard Harris, NPR's science correspondent, dives into the world of monoclonal antibody treatments for COVID-19, recently authorized by the FDA. He demystifies how these treatments work and their intended benefits for high-risk patients. Despite their emergency approval, Harris discusses their modest efficacy compared to vaccines. He also highlights logistical challenges in administering these therapies and the importance of continued preventive measures in managing the pandemic.

Richard Harris, a seasoned science correspondent, delves into the world of monoclonal antibody treatments for COVID-19. He discusses the FDA's emergency use authorizations for therapies from Eli Lilly and Regeneron, explaining that while these treatments are promising, their effectiveness isn't guaranteed. Harris breaks down how these antibodies function, their role in treating high-risk patients, and the logistical challenges they face. The conversation also highlights the comparison between monoclonal antibodies and vaccines in the broader fight against the pandemic.

Richard Harris, NPR's science correspondent, shares his expert analysis on President Trump's COVID-19 diagnosis and treatment. He discusses the implications of steroid use and supplemental oxygen in Trump's recovery, suggesting a severe case of the virus. The conversation unveils contradictions in health briefings, highlighting the need for transparency from medical teams. The political fallout of Trump's health on campaign strategies also comes into play, revealing how it impacts opponents like Joe Biden during this critical time.

NPR science correspondent Richard Harris dives deep into the current state of the pandemic, discussing the concerning rise in COVID-19 cases and the critical need for expanded testing. He highlights the impacts of premature state reopenings and the challenges posed by colder months ahead. With a focus on shifting demographics, he explains why younger racial groups are facing disproportionate mortality rates. Richard also addresses advancements in treatment and vaccination, offering insights on navigating the ongoing health crisis.

Richard Harris, NPR’s Science Desk correspondent, shares his expertise on the latest coronavirus developments during a virtual Senate committee hearing. He discusses the conflicting messages from health officials and lawmakers regarding economic reopening. Harris highlights the complexities of accurately reporting COVID-19 mortality rates and the impact of unaccounted deaths. The conversation also touches on the challenges of testing and contact tracing, emphasizing the importance of following scientific guidance amidst public health and economic pressures.